Jacqueline Diaz-Albertini

FDA investigator

Appears on 7 documents from 1996 to 2021, most often at sites in New York. Most often cites production record review (21 CFR 211.192).

7
Documents on file
4.8
Observations per 483
1996
First seen
2021
Most recent

What they cite most

From 22 observations

Activity by year

1996: 1, 2002: 1, 2013: 1, 2017: 1, 2019: 2, 2021: 1

Where

New York 2 · Switzerland 2 · Michigan 1 · North Carolina 1 · Washington 1

Is Jacqueline Diaz-Albertini coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

7 documents, newest first
FirmOpen
483 Jubilant HollisterStier LLCAug 31, 2021 · Spokane, Washington
483 Wyeth Pharmaceutical Division of Wyeth Holdings LLCNov 26, 2019 · Sanford, North Carolina
483 Protein Sciences CorporationMay 31, 2019 · Pearl River, New York
483 Bavarian Nordic Berna GmbHSep 22, 2017 · Thörishaus, Switzerland
483 Baxalta Manufacturing SàrlJul 12, 2013 · NEUCHÂTEL, Switzerland
483 Emergent Biodefense Operations Lansing LLCSep 13, 2002 · Lansing, Michigan
EIR New York Blood ServicesDec 20, 1996 · New York, New York

About this profile

What does Jacqueline Diaz-Albertini inspect?

Jacqueline Diaz-Albertini appears on 7 documents on file covering 6 sites, most often in New York.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.198 and 21 CFR 211.110.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Jacqueline Diaz-Albertini is dated Aug 31, 2021.